Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Growth 2026-2032
Description
The global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is a modified form of G-CSF designed to stimulate sustained production and release of neutrophils, a type of white blood cell vital for infection defense, over an extended period. Unlike short-acting G-CSF, which requires daily injections, long-acting G-CSF, such as pegfilgrastim, incorporates a polyethylene glycol (PEG) molecule that slows its breakdown and clearance from the body, allowing for prolonged therapeutic effects and reduced dosing frequency, typically once per chemotherapy cycle.
United States market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) players cover Amgen, Mylan, Kashiv BioSciences, Pfizer, Fresenius Kabi, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Forecast” looks at past sales and reviews total world Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) sales in 2025, providing a comprehensive analysis by region and market sector of projected Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) sales for 2026 through 2032. With Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) industry.
This Insight Report provides a comprehensive analysis of the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF).
This report presents a comprehensive overview, market shares, and growth opportunities of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Pegfilgrastim
Lenograstim
Other
Segmentation by Application:
Hospital and Clinic
Pharmacy
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Amgen
Mylan
Kashiv BioSciences
Pfizer
Fresenius Kabi
Coherus BioSciences
Sandoz
Italfarmaco SpA
Evive Biotech
Chugai Pharmaceutical
Jiangsu Hengrui Pharmaceuticals
Amoytop Biotech
Qilu Pharmaceutical
CSPC Baike Biopharma
SL Pharm
Lunan Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market?
What factors are driving Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market opportunities vary by end market size?
How does Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is a modified form of G-CSF designed to stimulate sustained production and release of neutrophils, a type of white blood cell vital for infection defense, over an extended period. Unlike short-acting G-CSF, which requires daily injections, long-acting G-CSF, such as pegfilgrastim, incorporates a polyethylene glycol (PEG) molecule that slows its breakdown and clearance from the body, allowing for prolonged therapeutic effects and reduced dosing frequency, typically once per chemotherapy cycle.
United States market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) players cover Amgen, Mylan, Kashiv BioSciences, Pfizer, Fresenius Kabi, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Forecast” looks at past sales and reviews total world Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) sales in 2025, providing a comprehensive analysis by region and market sector of projected Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) sales for 2026 through 2032. With Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) industry.
This Insight Report provides a comprehensive analysis of the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF).
This report presents a comprehensive overview, market shares, and growth opportunities of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Pegfilgrastim
Lenograstim
Other
Segmentation by Application:
Hospital and Clinic
Pharmacy
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Amgen
Mylan
Kashiv BioSciences
Pfizer
Fresenius Kabi
Coherus BioSciences
Sandoz
Italfarmaco SpA
Evive Biotech
Chugai Pharmaceutical
Jiangsu Hengrui Pharmaceuticals
Amoytop Biotech
Qilu Pharmaceutical
CSPC Baike Biopharma
SL Pharm
Lunan Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market?
What factors are driving Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market opportunities vary by end market size?
How does Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
126 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
